LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Strona główna・Stock List・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Closed

SectorHealthcare

9.94 1.64

Buy Sell

Overview

Share price change

24h

Current

Min

9.62

Max

9.98

Key metrics
By Trading Economics
Income	42M 17M
Sales	14M 169M
EPS	0.17
Profit margin	10.237
Employees	499
EBITDA	54M 48M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+62.37% upside

Market Stats
By TradingEconomics
Market Cap	678M 3B
Previous open	8.3
Previous close	9.94

News Sentiment

By Acuity

100%

358 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

5.925 / 7.38 Support & Resistance

Amicus Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 gru 2025, 20:41 UTC

Earnings

Major Market Movers

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4 gru 2025, 18:14 UTC

Acquisitions, Mergers, Takeovers

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4 gru 2025, 17:43 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4 gru 2025, 17:01 UTC

Earnings

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4 gru 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4 gru 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 gru 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4 gru 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4 gru 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 gru 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4 gru 2025, 21:37 UTC

Earnings

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4 gru 2025, 21:36 UTC

Earnings

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4 gru 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 gru 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4 gru 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4 gru 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4 gru 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4 gru 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 gru 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4 gru 2025, 16:33 UTC

Market Talk

Earnings

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer Comparison

Price change

Amicus Therapeutics Inc Forecast

Price Target

By TipRanks

62.37% upside

12 Months Forecast

Average 15.88 USD 62.37%

High 21 USD

Low 11 USD

Based on 8 Wall Street analysts offering 12 month price targets forAmicus Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Amicus Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.925 / 7.38Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

358 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.